Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835503 | 0.97 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL12835338 | 0.91 | TDP1 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL7085634 | 0.90 | CYP2D6 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL12835324 | 0.90 | TNKS (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL12835627 | 0.90 | CYP2D6 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL7087329 | 0.90 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL12835505 | 0.90 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL9327900 | 0.90 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL12835629 | 0.89 | CYP2D6 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 | |
| SCHEMBL9328614 | 0.89 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | NANOPROBES INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20250188143-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250186623-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| EP-4525834-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | Nanoprobes, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119386177-A | Multifunctional coordination polymer for activating hyperthermia induced in-situ vaccine and preparation method and application thereof | 中国药科大学 | 2025-02-07 | — | — | CN | claimed |
| EP-4489794-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| EP-4489795-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| US-20240423927-A1 | COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY | INSTITUT CURIE (FR) | 2024-12-26 | — | — | US | claimed |
| CN-119173281-A | Expression system for treating cancer | 应用医学研究基金会 | 2024-12-20 | — | — | CN | claimed |
| CN-119110733-A | Gene and radiation combination therapy for the treatment of cancer | 应用医学研究基金会 | 2024-12-10 | — | — | CN | claimed |
| US-20010041687-A1 | Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes | MRUK JOZEF S (US) | 2001-11-15 | — | — | US | claimed |
| WO-2001052839-A1 | USE OF FLAVONE 8-ACETIC ACID IN VASCULAR AND CARDIOVASCULAR INTERVENTIONS AND ACUTE CORONARY SYNDROMES | MRUK JOZEF S (US) | 2001-07-26 | — | — | WO | claimed |
| US-6071509-A | ADMINISTERING INTERLEUKIN, INTERFERON, OR FLAVONOID | MAXIM PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | claimed |
| US-6063373-A | ANTICARCER AGENT | MAXIM PHARMACEUTICALS, INC. (US) | 2000-05-16 | — | — | US | claimed |
| US-5585243-A | SEPARATELY INCUBATING HUMAN PLATELETS WITH BLOOD SAMPLE ANDREAGENT DRUG SOLUTION TO FORM COMPLEXES, DETERMINING AMOUNT OF BOUND ANTIBODY | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1996-12-17 | — | — | US | claimed |
| WO-1995008116-A1 | METHOD OF DETECTING CYTOPENIA THAT IS MEDIATED BY DRUG-DEPENDENT ANTIBODY BINDING TO BLOOD CELLS | THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) | 1995-03-23 | — | — | WO | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| US-5096707-A | Reanl carcinoma | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-03-17 | — | — | US | claimed |
| US-5061488-A | Flavone-8-acetic acid and interleukin-2 for cancer therapy | THE UNITED STATES OF AMERICA AS REPRESENTED DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1991-10-29 | — | — | US | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | VEGFA, FLT1, FLT4 | CYP1A2 3120/4885CYP3A4 1873/4885CYP2D6 3235/4885 |
| US-20010041687-A1 | Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes | F8, PLAT, MMP8 | CYP1A2 523/4885CYP3A4 1167/4885CYP2D6 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.